| 31.5 5.67 (21.95%) | 10-09 15:45 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 38.02  |
1-year : | 44.41 |
| Resists | First : | 32.55 |
Second : | 38.02 |
| Pivot price | 20.26 |
|||
| Supports | First : | 22.79 |
Second : | 16.77 |
| MAs | MA(5) : | 25.3 |
MA(20) : | 19.71 |
| MA(100) : | 19.91 |
MA(250) : | 21.99 |
|
| MACD | MACD : | 1.8 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 88.9 |
D(3) : | 84.5 |
| RSI | RSI(14): 85.3 |
|||
| 52-week | High : | 74.48 | Low : | 6.87 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NGNE ] has closed above the upper band by 18.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 221.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 27.46 - 27.54 | 27.54 - 27.63 |
| Low: | 22.89 - 22.97 | 22.97 - 23.07 |
| Close: | 25.66 - 25.81 | 25.81 - 25.97 |
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Thu, 09 Oct 2025
23 developmental milestones — Neurogene to start Embolden dosing in Q4 2025 after FDA talks and ICV data - Stock Titan
Wed, 08 Oct 2025
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference - Stock Titan
Sun, 05 Oct 2025
Neurogene Insiders Placed Bullish Bets Worth US$1.46m - Sahm
Fri, 03 Oct 2025
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - businesswire.com
Thu, 04 Sep 2025
Rare Disease Therapy Approvals By FDA Speed Up Via New Process - Neurogene (NASDAQ:NGNE) - Benzinga
Mon, 11 Aug 2025
Neurogene Inc. Reports Increased Losses Amid R&D Focus - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 9.2 (%) |
| Held by Institutions | 108.2 (%) |
| Shares Short | 2,820 (K) |
| Shares Short P.Month | 2,660 (K) |
| EPS | -4.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.1 % |
| Return on Equity (ttm) | -39.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -4.82 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -73 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -7.38 |
| PEG Ratio | 0 |
| Price to Book value | 1.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|